GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)

Last updated: October 21, 2024
Sponsor: GemVax & Kael
Overall Status: Completed

Phase

2

Condition

Progressive Supranuclear Palsy

Treatment

GV1001 1.12mg

GV1001 0.56mg

GV1001 Placebo

Clinical Study ID

NCT05819658
GV1001-PSP-CL2-011
  • Ages 41-85
  • All Genders

Study Summary

The study will be conducted by the Sponsor to evaluate the efficacy and safety of GV1001 (0.56 mg and 1.12 mg) administered subcutaneously as a treatment for Progressive Supranuclear Palsy, (PSP). In 75 patients diagnosed with PSPR Richardson(PSP-RS) or PSP-Parkinsonism (PSP-P) at five hospitals in Korea, subcutaneous administration of GV1001 0.56 or 1.12 mg/day will be conducted with multicenter, randomized, double-blind, placebo-controlled, parallel design, prospective phase 2a.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients aged ≥41 years to ≤ 85 years.

  • Clinical diagnosis of probable progressive supranuclear palsy (PSP).

  • Patient is on a stable therapy for a neurological drug for at least 1 month prior toscreening visit.

  • Patients who are able to walk 3 meters or more independently or with assistivedevices.

  • Score 15 points ≥ on the Korean Mini-Mental Status Exam (K-MMSE) at the screeningvisit.

  • Have reliable caregiver to accompany participant to all study visits.

  • Patients and/or their representatives who have voluntarily provided a writtenconsent for participation in this clinical study.

Exclusion

Exclusion Criteria:

  • Patients who have Presence of structural lesions or Suspected concurrent onset ofcentral nervous system diseases based on the CT/MRI scan results and neurologicalexaminations performed within 12 months of screening or at screening.

  • Patients with a history of known or suspected seizures.

  • Patients with a recent unexplained loss of consciousness within 3 months prior toscreening or a history of significant head trauma with loss of consciousness.

  • Patients with acute or unstable cardiovascular disease, uncontrolled hypertension,uncontrolled diabetes, or any other medical condition that can interfere withcompleting the clinical study.

  • Patients with hypersensitivity reactions to the ingredients of the investigationalproduct.

  • Patients with a history of cancer within 5 years prior to screening.

  • Patients with abnormal renal function.

  • Patients with severe liver function abnormalities.

  • Patients weighing ≤35 kg.

  • Among the female subjects who does not agree to use proper contraception.

  • Pregnant or breastfeeding women.

  • Patients who participated in another clinical study within 4 weeks prior toscreening and were administered investigational products or were appliedinvestigational medical devices.

  • Patients who were administered the study drug (GV1001) of this clinical study within 12 months prior to screening.

  • Patients who participated in a clinical study for progressive supranuclear palsywithin 6 months prior to screening.

  • Other patients judged by the investigator as ineligible to participate in thisclinical study.

Study Design

Total Participants: 78
Treatment Group(s): 3
Primary Treatment: GV1001 1.12mg
Phase: 2
Study Start date:
June 14, 2023
Estimated Completion Date:
October 11, 2024

Study Description

This is a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel design, prospective, Phase 2a exploratory clinical study. If the subject and/or the subject's representative provide a written consent to participate in this clinical study, the required examinations and tests will be performed at the screening visit, and the screening period will run for 4 weeks or shorter. Subjects who are ultimately determined as eligible by the inclusion/exclusion criteria after screening will be randomized at a 1:1:1 ratio to Study Group 1 (GV1001 0.56 mg/day), Study Group 2 (GV1001 1.12 mg/day), or the placebo group depending on the study site in which they are enrolled. Depending on the randomization results, subjects will be administered the investigational product (study drug or placebo) once weekly for the first 4 weeks (1 month), and then administered 10 times at 2-week intervals for 20 weeks (5 months) for a total of 14 doses over 24 weeks (6 months). All subjects will visit the institution according to the planned clinical study schedule to receive the investigational product and to be evaluated for efficacy and safety. To ensure the objectivity and accuracy of the study results, the individuals evaluating efficacy will be limited to neurologists who have been sufficiently educated and trained, and the collection of efficacy and safety evaluation data and biomarkers will be performed in a consistent order at each visit.

Connect with a study center

  • Seoul National University Bundang Hospital

    Seongnam-si,
    Korea, Republic of

    Site Not Available

  • Kyung Hee University Hospital

    Seoul,
    Korea, Republic of

    Site Not Available

  • Kyung Hee University Medical Center

    Seoul,
    Korea, Republic of

    Site Not Available

  • Samsung Medical Center

    Seoul,
    Korea, Republic of

    Site Not Available

  • Seoul Metropolitan Government Seoul National University Boramae Medical Center

    Seoul,
    Korea, Republic of

    Site Not Available

  • Seoul National University Hospital

    Seoul,
    Korea, Republic of

    Site Not Available

  • Smg-Snu Boramae Medical Center

    Seoul,
    Korea, Republic of

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.